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ABSTRACT 25 
 26 
There is conflicting evidence of the impact of commonly used antiretroviral therapies (ARTs) on 27 
the pharmacokinetics of lumefantrine and safety profile of artemether-lumefantrine. We 28 
compared the area under the concentration-time curve (AUC0-14 days) of lumefantrine and safety 29 
profile of artemether-lumefantrine in malaria-negative human immunodeficiency virus (HIV) 30 
infected adults in two steps. In step 1, a half-dose adult course of artemether-lumefantrine was 31 
administered as a safety check in four groups (n=6/group): (i) antiretroviral-naïve, (ii) on 32 
nevirapine-based ART, (iii) on efavirenz-based ART and (iv) on ritonavir-boosted lopinavir-33 
based ART. In step 2, a standard-dose adult course of artemether-lumefantrine was 34 
administered to a different cohort in three groups (n=10-15/group): (i) antiretroviral-naïve, (ii) on 35 
efavirenz-based ART and (iii) on ritonavir-boosted lopinavir-based ART. In step 1, 36 
lumefantrine’s AUC0-14 days was 53% [95% CI: 0.27-0.82] lower in the efavirenz-based ART group 37 
than the ART-naïve group and was 2.4 [95% CI: 1.58-3.62] and 2.9 [95% CI: 1.75-4.72] times 38 
higher in the nevirapine and ritonavir-boosted lopinavir groups, respectively. In step 2, 39 
lumefantrine’s AUC0-14 days was 1.9 [95% CI: 1.26-3.00] times higher in the ritonavir-boosted 40 
lopinavir group and not significantly different between the efavirenz- and ART-naïve groups 41 
(0.99 [95% CI: 0.63-1.57]). Frequent cases of haematological abnormalities (thrombocytopenia 42 
and neutropenia) were observed in the nevirapine group in step 1, leading to a recommendation 43 
from the data and safety monitoring board not to include a nevirapine group in step 2. 44 
Artemether-lumefantrine was well tolerated in the other groups. The therapeutic implications of 45 
these findings need to be evaluated among HIV-malaria co-infected adults. 46 
 47 
Key words: Artemether-lumefantrine; Antiretroviral therapy; Malaria 48 
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INTRODUCTION  50 
In sub-Saharan Africa (SSA), human immunodeficiency virus (HIV) and Plasmodium falciparum 51 
(Pf) malaria infections are co-endemic. HIV infection increases susceptibility to malaria (1–3), 52 
severity of Pf malaria  and reduces the efficacy of some antimalarial drugs (4, 5). To combat 53 
these infections, the WHO recommends initiation of antiretroviral therapy (ART) in HIV-positive 54 
(HIV+) individuals regardless of their CD4 cell counts (6) and prompt use of artemisinin-based 55 
combination therapies (ACTs) for malaria infected individuals (7). The most commonly used 56 
ART in SSA contain non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz 57 
(EFV) and nevirapine (NVP) or protease inhibitors (PIs) such as ritonavir-boosted lopinavir 58 
(LPV/r). Artemether-lumefantrine (AL) is the most widely implemented first line ACT in the SSA 59 
region (3). HIV-malaria co-infection is common in SSA hence a large number of HIV+ people on 60 
ART require concurrent treatment with AL.  61 
 62 
Pharmacokinetic (PK) interactions between NNRTI or PI-containing ART and ACTs are likely 63 
since these classes of drugs affect the activity of cytochrome-P(CYP) 450 liver enzymes, 64 
including CYP3A4 and CYP2B6 (8–11). The interactions may impact the longer acting partner 65 
drug of an ACT which is vital in preventing post-treatment malaria recrudescence, after the rapid 66 
elimination of the artemisinins (12). Previous PK studies have found lower lumefantrine levels in 67 
healthy volunteers co-treated with AL and EFV-based ART and higher lumefantrine levels in 68 
those co-treated with AL and LPV/r-based ART when compared to those treated with AL only 69 
(13–15). However, PK studies on AL and NVP-based ART, have produced conflicting results, 70 
with some finding higher, lower or similar lumefantrine levels in HIV+ individuals on NVP-based 71 
ART than ART-naive individuals treated with AL only (16–20). Furthermore, few studies have 72 
reported the safety profiles of co-administering AL with commonly used antiretroviral drugs in 73 
HIV infected individuals stabilized on ART.  74 
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To further characterize the impact of nevirapine-, efavirenz-, or ritonavir-boosted lopinavir -75 
based ART on the PK of lumefantrine and safety profile of AL, we conducted an intensive PK 76 
study to compare secondary PK parameters of lumefantrine and the incidence of treatment-77 
emergent adverse events in malaria-negative HIV-infected adults taking AL plus NVP-, EFV-, or 78 
LPV/r -based ART or AL only. 79 
 80 
MATERIALS AND METHODS 81 
 82 
Study design 83 
An open-label, sequential group, PK study was conducted from August 2010 to March 2013 at 84 
Queen Elizabeth Central Hospital, in Blantyre, Malawi. The study was implemented in the 85 
following two steps: In step 1 [PACTR2010030001871293], a half adult dose of the AL (2 86 
tablets of AL [Coartem®, Novartis] each tablet containing 20mg/120mg, 87 
artemether/lumefantrine) was administered at times 0, 8, 24, 36, 48 and 60 hours to malaria-88 
negative HIV+ individuals in the following groups: 1) an antiretroviral naive (control) group, and 89 
those receiving 2) NVP-based ART, 3) EFV-based ART and 4) LPV/r-based ART. This step 90 
served mainly as a preliminary safety evaluation, checking for unexpected clinical toxicities or 91 
interactions.  92 
 93 
In step 2 [PACTR2010030001971409], after review of safety data from step 1 by an 94 
independent data and safety monitoring board (DSMB), a full standard dose of AL (4 tablets of 95 
Coartem®, each tablet containing 20mg/120mg AL) was administered at times 0, 8, 24, 36, 48 96 
and 60 hours to a separate cohort of malaria-negative HIV+ individuals in the following groups: 97 
1) an antiretroviral naive (control) group, and those receiving 2) EFV-based ART and 3) LPV/r-98 
based ART. The DSMB recommended that step 2 should not proceed with a NVP-based ART 99 
group because of safety concerns. 100 
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To maximize the absorption of lumefantrine, AL was given with ~40 millilitres of soya milk, 101 
containing an equivalent of 1.2g of fat. The first dose of AL in ART participants was timed to 102 
coincide with the next scheduled dose of the antiretroviral drugs.  103 
 104 
Study population  105 
The study population for step 1 and step 2 were HIV infected male and non-pregnant female 106 
adults aged ≥18 years residing in Blantyre, Malawi or neighbouring districts of Thyolo and 107 
Chiradzulu. Individuals on ART were eligible to participate if they had been on NNRTI or PI-108 
based ART for ≥ 6 months and had CD4 cell count ≥ 250 cells/mm3. At the beginning of the 109 
study, HIV infected antiretroviral naive individuals were eligible if they had CD4 cell count ≥ 110 
250/mm3 but this cut-off point was changed to ≥350/mm3 when the WHO criteria for ART 111 
initiation changed in July 2011. Other inclusion criteria were body weight ≥40kgs, willingness to 112 
be admitted in the hospital for 3 days, to remain within the study sites and to be contacted at 113 
home or by phone during the course of the study.  114 
 115 
We excluded subjects who had a body mass index of <18.5kg/m2, haemoglobin concentration of 116 
<10 g/dL (subsequently changed to <8.5 g/dL based on DSMB recommendation), reported use 117 
of any antimalarial drugs within the preceding 4 weeks, reported hypersensitivity to any of the 118 
ACTs , receipt of  other drugs which are known inhibitors or inducers of P450 enzymes or P-119 
glycoprotein (except cotrimoxazole prophylaxis which was standard of care for HIV infected 120 
individuals), a history of regular intake of alcohol (>twice/week), tobacco (>3 times/week) or any 121 
use of illicit drugs, history or evidence of pre-existing liver, kidney or heart disease, including 122 
conductive abnormalities on electrocardiographs (QTc interval>450ms in men and >470ms in 123 
females), clinical and/or laboratory evidence of Pf malaria, hepatitis B, pneumonia, tuberculosis, 124 
bacteremia, laboratory evidence of potentially life threatening white blood cell disorders such as 125 
absolute neutrophil count <0.500*109/L, absolute lymphocyte count <0.35*109/L or absolute 126 
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platelet count <25*109/L, Karnofsky score of <80% or concurrent participation in any other 127 
clinical trial. 128 
 129 
Sample size 130 
The sample size in step 1 was 6 in each of the AL/ART and control (ART-naive) and this was 131 
based on standard practice in early PK studies of antimalarial drugs which aim to safeguard the 132 
safety of study subjects and minimize the number of subjects who may be potentially exposed 133 
to harmful drug levels. In step 2, the sample size was 15 per group which had at least 90% 134 
power to detect a two-fold increase in lumefantrine AUC in any of the AL/ART groups compared 135 
with the ART-naive group, assuming a mean (standard deviation) lumefantrine AUC of 0.561 136 
(0.36) μg/mL/hr (15) in the ART-naive group, at the level of significance of 5%.  137 
 138 
Ethics and screening procedures  139 
The design and timing of trial procedures was approved by the College of Medicine Research 140 
Ethics Committee (COMREC), in Blantyre, Malawi. The study conformed to the principles of the 141 
International Conference on Harmonization on Good Clinical Practice. Research nurses and 142 
clinicians sought written informed consent from individuals to perform screening procedures 143 
including physical, medical and anthropometric assessment, electrocardiographs (ECGs) and 144 
blood tests to detect blood-borne infections, haematological, renal or hepatic abnormalities. 145 
Results from screening procedures were available within seven days of screening. Based on 146 
these results, potential study participants were informed of their eligibility to participate in the 147 
study. Thereafter, research nurses or clinicians sought written informed consent from eligible 148 
subjects to participate in the study.  149 
 150 
 151 
 152 
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Pre-dosing procedures 153 
Consenting study participants were re-assessed by research nurses or clinicians to determine 154 
whether they still met all eligibility criteria, through repeat history taking and physical 155 
examination. Eligible participants were admitted in hospital and an indwelling cannula was 156 
inserted into a vein before their scheduled dose of ART and the first dose of the ACT. 157 
Approximately 1 hour before the scheduled time of ART and ACT dosing, blood samples were 158 
collected for haematological, renal and liver function tests and random glucose test. 159 
 160 
Blood sample collection and processing 161 
During hospitalization, blood samples for PK assays were collected in heparin tubes before 162 
treatment and at 1, 2, 4, 6, 12, 24, 36, 48, 60 and 72 hours post treatment. After discharge, 163 
blood samples were taken at 4, 5, 6, 7 and 14 days. Immediately after collection, the blood 164 
samples were spun in a refrigerated centrifuge and the separated plasma samples were 165 
temporarily frozen in liquid nitrogen before being transferred to a -80˚C freezer until PK 166 
analyses.  167 
 168 
Safety assessments 169 
After the first dose of AL, blood samples were collected to detect haematological, renal and liver 170 
function abnormalities at 12, 48 and 72 hrs and on day 7, 14, 21 and 28. In addition, in step 2, 171 
12-lead electrocardiographs were performed pre-dosing, 5 hours after the first dose and 5 hours 172 
after the last dose to determine QTc interval using the Fridericia QT correction formula (21). The 173 
study focussed on treatment emergent adverse events (AEs) defined as “any clinical or 174 
subclinical abnormalities which were absent before dosing with AL but emerged post dosing or 175 
those which were present before dosing with AL but worsened post-dosing”. Severity of AEs 176 
was graded using the DAIDS criteria (22) while seriousness was defined according to the 177 
standard definition.  178 
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Pharmacokinetic assays   179 
Plasma samples were analysed for lumefantrine levels at the Malawi-Liverpool Wellcome Trust 180 
Clinical Research Programme in Blantyre, Malawi, using a validated HPLC-UV assay adopted 181 
and transferred to Malawi from Liverpool School of Tropical Medicine. The PK laboratory in 182 
Blantyre participated in WWARN’s External Quality Assurance programme (23). Briefly, 183 
lumefantrine and the internal standard (IS, Halofantrine), were recovered from plasma using a 184 
single protein precipitation step with acetonitrile and acetic acid (99:1). The supernatant was then 185 
evaporated to dryness in a vacuum concentrator at 25 0C. The dried extract was re-dissolved in 186 
the reconstitution solvent methanol: hydrochloric acid 0.01M (70:30) and 75 µL injected into the 187 
chromatograph (Agilent 1100). Quantitation of the drugs was achieved by reverse phase HPLC. 188 
The optimum detection wavelength for each drug was 335 nm. The lower limit of quantification 189 
(LLQ) of the HPLC-UV assay was 0.05 µg/mL for lumefantrine with % coefficient of variation of 190 
<10. Extracted plasma pharmacokinetic samples were run in batches comprising of all samples 191 
collected from each of any two study participants. Each batch run included a blank plasma 192 
extract, two sets of 8-concentration-level calibration standards, and quality controls (QC) at 193 
three concentration levels: low, medium and high (0.05, 10 and 15 µg/mL). For batch assay to 194 
pass, the measured concentrations of at least 67% of the QC samples had to be within +/-20% 195 
of their nominal value and at least one QC had to be acceptable at the LLQ. The mean inter-196 
assay precision for low, medium and high QCs was 6.6%, 8.8% and 9.2% respectively. In 197 
addition, 75% of each calibration curve's concentrations had to lie within +/-20% and +/-15% of 198 
the nominal concentration at the LLQ or all other concentrations, respectively.  199 
 200 
Data analyses  201 
Plasma concentrations of lumefantrine were analysed using non-compartmental 202 
pharmacokinetic analysis (NCA), employing the trapezoidal rule with cubic splines. Observed 203 
lumefantrine concentrations below the lower limit of quantification (<LLOQ) were treated as 204 
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missing data except for the pre-dose lumefantrine concentration which was imputed to 0 if 205 
below LLOQ. For each study participant, the following PK parameters were computed: AUC0-14 206 
days, maximum concentration [Cmax], time to maximum concentration [tmax] and terminal 207 
elimination half-life [t1/2]). We used STATA 15.0 for the NCA and to compare log-transformed PK 208 
parameters. Geometric mean ratios with 95% confidence intervals have been presented. To test 209 
for significant differences in PK parameters between each ACT/ART group and the ART-naïve 210 
group, parametric evaluation of the log-transformed PK parameters was done using analysis of 211 
variance (ANOVA) (α=0.05). Fisher’s exact test was used to compare proportions of participants 212 
across the study groups with day 7 concentrations that were above a value known to predict 213 
treatment response by day 28, and of safety parameters across the different ACT/ART groups 214 
in comparison to the ART naïve group. Data summaries and graphics were all performed in 215 
STATA 15.0.  216 
 217 
RESULTS 218 
Characteristics of participants 219 
In step 1, 26 participants were enrolled in the study; 24 participants were successfully followed 220 
up for 28 days. Two participants taking NVP-based ART were discontinued from the study due 221 
to protocol deviations and are not included in the analyses. In step 2, 40 of the 43 enrolled study 222 
participants completed 28 days of follow-up. Three participants did not have sufficient data 223 
points for PK characterization and are not included in the analyses. No participants were 224 
enrolled in the NVP arm for step 2 on the advice of the DSMB because of the observed 225 
haematological abnormalities in step 1. Supplementary Table 1 shows the baseline 226 
characteristics of participants who completed follow-up in steps 1 and 2. In step 1, the median 227 
duration of ART (in months) was significantly longer in the LPV/r group (63.1, range [33.3-85.0]) 228 
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than in the EFV group (25.1, range [7.8-49.3]) and the NVP group (58.8, range [24.7-80.6]). 229 
There were no major differences between baseline characteristics in step 1 or step 2.   230 
 231 
Pharmacokinetics of lumefantrine and interactions with antiretroviral therapy in step 1 232 
Table 1 summarizes the PK parameters in the study groups in step 1. Compared with the ART-233 
naïve group, the geometric mean AUC0-14 days of lumefantrine was 53% lower in the EFV-ART 234 
group, 2.4 times higher in the NVP-ART group and 2.9 times higher in the LPV/r-based ART 235 
group. Similarly, compared with the ART naïve group, lumefantrine’s Cmax was 37% lower in the 236 
EFV-ART group, 1.9 times higher in the LPV/r-ART group and not significantly different in the 237 
NVP based ART arm. Additionally, compared with the ART naïve group, lumefantrine’s terminal 238 
half-life was 61% shorter in the EFV-group but not significantly different in the LPV/r-based and 239 
NVP-based ART groups. The median tmax was similar in the NVP-, EFV-based and ART-naïve 240 
groups but slightly longer in the LPV/r-based ART group than in the ART naïve group with 241 
marginal significance. As illustrated in the concentration-time profile in Figure 1, participants in 242 
the LPV/r- and NVP-ART groups had higher concentrations of lumefantrine in the terminal 243 
elimination phase than those in the ART naïve sub-group, while those in the EFV-based ART 244 
group had lower lumefantrine concentrations.  245 
 246 
Artemether-Lumefantrine tolerability and treatment-emergent adverse events in step 1.  247 
AL was well tolerated in all the groups. However, DAIDS grade 3 or 4 treatment-emergent 248 
neutropenia were frequently detected across all the study groups: ART-naïve (3/6 [50.0%]), 249 
EFV-based ART (1/6 [16.7%]), LPV/r-based ART (2/6 [33.3%]) and NVP-based ART (3/6 250 
[50.0%]). The inter-group differences were not statistically significant. Additionally, DAIDS grade 251 
3 or 4 treatment-emergent thrombocytopenia was detected in the NVP-based ART (2/6 [33.3%]) 252 
but not in the ART-naïve or the LPV/r- and EFV-based ART groups. There was lack of evidence 253 
of a correlation between neutropenia or thrombocytopenia and measured lumefantrine 254 
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concentration and none of these observed adverse events were persistent beyond day 14 of 255 
follow up. 256 
 257 
Pharmacokinetics of lumefantrine and interactions with antiretroviral therapy in step 2 258 
Table 2 summarizes the PK parameters in the study groups in step 2. The geometric mean 259 
lumefantrine AUC0-14 days was similar in the EFV-based ART group and the ART-naïve group. 260 
Participants in the LPV/r-based ART group had an approximately 1.9 times higher geometric 261 
mean AUC0-14 days than those in the ART naïve group. There were no significant differences in 262 
Cmax, t1/2 and median tmax in the EFV- and LPV/r-based ART groups compared to the ART-naïve 263 
group. As illustrated in the concentration-time profile in Figure 2, lumefantrine concentrations 264 
were higher in the LPV/r-based ART than the ART-naïve group and were persistently lower in 265 
the terminal elimination phase (after 72 hours) in the EFV-based ART group than the ART-naïve 266 
group. 267 
 268 
Day 7 lumefantrine concentrations in step 2  269 
Upon administration of a full standard AL dose, day 7 mean lumefantrine was 50% lower in the 270 
EFV-based ART group than in the ART-naïve group. Participants in the LPV/r-based ART group 271 
had 4 times higher day 7 lumefantrine concentration compared to those in the ART-naïve group 272 
as shown in Table 2. However, the proportion of participants with day 7 lumefantrine 273 
concentrations ≥0.2 µg/mL (200 ng/mL) were not significantly different in the ART-naïve group 274 
(100% [10/10]), LPV/r-based ART group (100% [15/15]) and EFV-based ART group (86.7% 275 
[13/15]).  276 
 277 
Artemether-Lumefantrine tolerability and treatment-emergent adverse events in step 2.  278 
AL was well tolerated in the three study groups:  no DAIDS grade 3 or 4 haematological 279 
abnormalities (neutropenia or thrombocytopenia) were reported across the groups. On day 3, 280 
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QTc prolongation (>450ms) was observed in 1 participant in EFV-based ART group and another 281 
in the ART-naive group but none in the LPV/r-ART group.  All cases resolved by day 7.   282 
 283 
DISCUSSION 284 
 285 
This study found that, when treated with a half-dose adult course of AL, individuals on EFV-286 
based ART regimen had lower lumefantrine exposure (AUC0-14 days) than ART-naïve individuals 287 
while those on NVP- or LPV/r-based ART groups had higher AUC0-14 days. Similarly, compared to 288 
the ART-naïve group, Cmax was lower in the EFV-based ART group, higher in the LPV/r- based 289 
ART group and similar in the NVP-based ART group. There were no differences in tmax across 290 
the study groups. The terminal-half life was significantly lower in the EFV-based ART group but 291 
similar in the LPV/r- or NVP-based ART groups when compared to the ART-naïve group. 292 
DAIDS grade 3 or 4 treatment-emergent thrombocytopenia and neutropenia were observed 293 
upon co-administration of AL and NVP-based ART. When treated with a standard-dose adult 294 
course of AL, there was no statistically significant difference in lumefantrine AUC0-14 days between 295 
the EFV- based ART group and the ART-naïve group but those on LPV/r-based ART had higher 296 
AUC0-14 days than the ART-naïve group. There were no significant differences in terminal half-life, 297 
Cmax and tmax between the ART-groups and the ART-naïve group. Additionally, AL was well 298 
tolerated across all study groups. 299 
 300 
Our finding, in both steps, of a higher lumefantrine exposure (AUC0-14 days) and Cmax in the LPV/r-301 
based ART group is consistent with what is known about ritonavir-boosted lopinavir inhibition of 302 
CYP450 enzymes (CYP3A4), resulting in higher plasma lumefantrine concentration since 303 
lumefantrine is metabolised by this enzyme entity (13, 14, 24). The therapeutic implications of 304 
this observation have been previously shown among Ugandan children who had a reduced 305 
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incidence of malaria when taking lumefantrine and lopinavir-based ART compared to those on 306 
NNRTI-based ART (15).  307 
 308 
Unlike in step 1, where lumefantrine exposure in the EFV-based ART group was significantly 309 
lower in comparison to the ART-naïve group, overall lumefantrine exposure (AUC0-14 days) in step 310 
2 was surprisingly not significantly different between the two groups. Lumefantrine 311 
concentrations in the terminal elimination phase however, were consistently lower in the EFV-312 
based ART group compared to the ART-naïve group in both steps (Figures 1a and 1b). Since 313 
EFV is a known inducer of CYP3A4 enzymes (9), lower lumefantrine concentrations were 314 
expected in the terminal elimination phase. The difference in lumefantrine exposure in the EFV-315 
ART / ART-naïve comparison could be as a result of the use of a parallel-group study design, 316 
which is more prone to effects of inter-individual anthropometric and genetic variations in 317 
CYP450 enzymes than in a cross-over design. Genetic polymorphisms in CYP450 enzymes are 318 
known to impact exposure of drugs metabolised by this enzyme entity (25, 26).  Nevertheless, 319 
the lower lumefantrine concentrations in the elimination phase among participants on efavirenz-320 
based ART in step 2 is consistent with previous observations (27).  321 
 322 
There are conflicting published results on the PK interactions between AL and NVP-ART, with 323 
studies suggesting higher (16, 28), lower (18, 24) or similar (17, 19) lumefantrine exposure in 324 
those on AL and NVP-based ART compared to individuals on AL alone. This heterogeneity 325 
potentially points to genetic variations in CYP activity across HIV-malaria endemic settings. We 326 
found higher concentrations of lumefantrine in the NVP-based ART group in step 1 than in the 327 
ART naïve group, consistent with findings from an earlier study in South Africa (16) and another 328 
study conducted in Malawi and Uganda (28). There is evidence that NVP may increase 329 
exposure of other drugs metabolised by the CYP3A4 results as shown with increased Cmax and 330 
AUC of darunavir (29) and maraviroc (30), when co-administered with nevirapine, possibly due 331 
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to reduced metabolism secondary to competitive inhibition of metabolic enzymes (31) or as a 332 
result of variations in availability of proteins to transport drugs (32). Thus, the increased AUC0-14 333 
days and Cmax of lumefantrine in the NVP-based ART group could suggest reduced CYP3A4-334 
mediated metabolism or unavailability of proteins to transport lumefantrine.  Alternatively, the 335 
higher exposure of lumefantrine in the NVP-based ART group could be due to potential 336 
distinctive inhibition of CYP isoenzymes, such as CYP2C9/19, by NVP which could be different 337 
from that exhibited by other NNRTIs (e.g. EFV). This phenomenon, of drug- compared to class 338 
specific inhibition of liver metabolic enzymes by ART, has been previously shown in animal 339 
models when ART is co-administered with gliclazide (33) 340 
 341 
Neutropenia has been previously documented when ACTs such as artesunate-amodiaquine 342 
were administered among HIV infected children in Uganda (34). In addition, NVP is associated 343 
with granulocytopenia as a marker of hypersensitivity (35) but its role in causing 344 
thrombocytopenia has not been described. Thus, it is possible that neutropenia could occur 345 
following co-administration of NVP and lumefantrine as a result of increased lumefantrine 346 
concentration, increased NVP concentrations or a synergistic effect of lumefantrine and NVP. In 347 
our study population, the occurrence of cases of grade 3 or 4 neutropenia across all study 348 
groups in step 1, which were not observed at higher doses in step 2, is likely idiosyncratic since 349 
cases of asymptomatic neutropenia have also been previously observed in healthy Malawian 350 
adult blood donors (36). Apart from the underlying HIV infection, and with the exception of those 351 
on LPV/r-based ART who took it together with zidovudine-ART, none of the participants who 352 
experienced thrombocytopenia had other baseline predisposing factors, such as low immunity 353 
(CD4 <500 cells/mm3) or low platelet count. Furthermore, no previous studies have found an 354 
association between NVP and thrombocytopenia. The finding of thrombocytopenia in the group 355 
receiving AL and NVP- is therefore surprising and could be due to chance. Nevertheless, the 356 
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data and safety monitoring board recommended against administration of a standard-dose adult 357 
course of AL with NVP due to the frequent occurrence of thrombocytopenia in addition to 358 
neutropenia in the NVP group compared to the ART-naïve group in step 1. We, therefore, were 359 
unable to investigate the effect of co-administration of a standard-dose adult course of AL and 360 
NVP on the incidence of thrombocytopenia. 361 
 362 
Day 7 lumefantrine concentrations are considered to be one of the most important predictors of 363 
treatment outcomes following malaria treatment (37, 38). Various investigators have suggested 364 
different day 7 lumefantrine cut-offs (39–47) and in a pooled analysis, the WorldWide 365 
Antimalarial Resistance Network (WWARN) observed that day 7 lumefantrine concentrations ≥ 366 
0.2 μg/mL (200 ng/mL) were associated with a 98% cure rate in uncomplicated malaria patients 367 
(parasitaemia <135,000/μL) (48). In step 2 of this study, although participants on EFV-ART had 368 
lower day 7 lumefantrine concentrations than ART-naïve participants and those on LPV/r-based 369 
ART had higher concentrations, the proportion achieving lumefantrine concentration ≥0.2 μg/mL 370 
was only slightly lower in the EFV-ART group but was not significantly different from the ART-371 
naïve group. This suggests that AL is still likely to be highly efficacious in those on EFV-based 372 
ART, despite the PK interaction.  373 
 374 
In this study, we did not assess impact of ART on plasma concentrations of the artemisinin 375 
derivatives (artemether and its metabolite, dihydroartemisinin) which have a shorter half-life and 376 
are crucial in clearing malaria parasites in the early phases of malaria treatment, because we 377 
were interested in the longer acting drug, lumefantrine, which confers protection against 378 
recrudescence following malaria infection (39, 49). Additionally, we did not quantify NVP plasma 379 
concentrations and were not able to assess any potential effect of lumefantrine on the steady-380 
state concentration changes of NVP as well as subsequent impact on haematological changes. 381 
Other limitations include the lack of participant randomization during enrolment and potential for 382 
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unmeasured confounders which may have influenced the observed lumefantrine kinetics. 383 
Although the present study had a small sample size, it is unlikely to have missed large (>2-fold) 384 
clinically important differences in AUC across the study arms. Furthermore, this study was not 385 
designed to elucidate the mechanism of interaction between lumefantrine and ART. Future 386 
studies should aim to define these mechanisms, including the role of genetic variations in 387 
CYP450 isoenzyme activity and the impact of ART on plasma concentrations of artemisinin 388 
derivatives and subsequent implication on clearance of malaria parasites among HIV-malaria 389 
co-infected individuals. 390 
 391 
In conclusion, we confirmed that co-administration of AL with ritonavir-boosted lopinavir-based 392 
antiretroviral therapy resulted in increased lumefantrine exposure while co-administration of AL 393 
with EFV-based ART was associated with lower lumefantrine concentrations, particularly in the 394 
terminal elimination phase. Co-administration of AL and NVP-ART was associated with higher 395 
lumefantrine exposure and haematological abnormalities (thrombocytopenia and neutropenia) 396 
at half-dose adult course of AL. The therapeutic implications of these findings need to be 397 
evaluated in programmatic settings among malaria and human immunodeficiency virus co-398 
infected individuals. 399 
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LEGENDS 617 
 618 
Figure 1. Plasma lumefantrine concentration-time profile in step 1 following administration of 619 
half (n=24) adult treatment course of artemether-lumefantrine among antiretroviral therapy 620 
naïve (blue), those on efavirenz- (red), nevirapine- (green), and ritonavir-boosted lopinavir- 621 
(black) based antiretroviral therapy. Data are presented as median (IQR). 622 
 623 
Figure 2. Plasma lumefantrine concentration-time profile in step 2 following administration of 624 
full-adult treatment course (n=40) of artemether-lumefantrine among antiretroviral therapy naïve 625 
(blue), those on efavirenz- (red) and ritonavir-boosted lopinavir- (black) based antiretroviral 626 
therapy. Data are presented as median (IQR). 627 
 628 
 629 
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Table 1: Lumefantrine pharmacokinetic parameters for participants in step 1 
 
  
  Study groups   Geometric Mean Ratio [95% CI] (p-value) 
  ART naïve                      
n=6 
NVP                              
n=6 
LPV/r                                    
n=6 
EFV                                  
n=6 
NVP/ART naïve LPV/r/ART naïve EFV/ART naïve 
AUC0-14 days, 
hr.µg/mL 
513 [374-703] 1226 [943-1594] 1476 [1019-2139] 239 [152-377] 2.39 [1.58-3.62] (0.001) 2.88 [1.75-4.72] (0.001) 0.47 [0.27-0.82] (0.018) 
Cmax (µg/mL) 8 [6-10] 12 [8-17] 15 [11-20] 5 [3-7] 1.50 [1.00-2.23] (0.119) 1.88 [1.28-2.68] (0.016) 0.63 [0.36-0.89] (0.054) 
tmax (hr) 54 [48-72] 72 [48-72] 72 [72-72] 36 [12-72] 0.295
a
 0.060
a
 0.365
a
 
t1/2 (hr) 152 [72-322] 185 [162-212] 223 [171-291] 60 [44-82] 1.22 [0.57-2.62] (0.597) 1.47 [0.66-3.26] (0.341) 0.39 [0.18-0.90] (0.039) 
PK parameters are presented as geometric mean [95% confidence interval] except tmax which is presented as median [interquartile range].  
P-value is calculated using aŶalǇsis of variaŶce iŶ Stata ϭ5.Ϭ, α=Ϭ.Ϭ5 
 
  
ART = antiretroviral therapy; NVP = Nevirapine-based ART; EFV = Efavirenz-based ART; LPV/r = Ritonavir-boosted lopinavir-based ART 
 AUC0-14 days = area under concentration-time curve from 0 hours to 14 days; Cmax = achieved maximum concentration. 
 tmax = time to reach maximum concentration, t1/2 = drug elimination half-life 
 
  
a: p-value oŶlǇ, calculated usiŶg WilcoǆoŶ raŶk suŵ test, α=Ϭ.Ϭ5 
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Table 2: Lumefantrine pharmacokinetic parameters for participants in step 2 
 
  Study groups   Geometric Mean Ratio [95% CI] (p-value) 
  ART naïve                               
n=10 
LPV/r                                        
n=15 
EFV                                           
n=15 
LPV/r/ART naïve EFV/ART naïve 
AUC0-14 days, 
hr.µg/mL 
1084 [760-1547] 2107 [1654-2686] 1081 [816-1432] 1.94 [1.26-3.00] (0.004) 0.99 [0.63-1.57] (0.991) 
Cmax (µg/mL) 15 [10-23] 19 [16-23] 18 [14-23] 1.27 [0.81-1.93] (0.265) 1.20 [0.75-1.84] (0.456) 
tmax (hr) 66 [24-72] 72 [60-72] 48 [12-72] 0.145
a
 0.340
a
 
t1/2 (hr)* 160 [103-248] 190 [154-236] 102 [61-170] 1.19 [0.73-1.94] (0.438) 0.64 [0.32-1.26] (0.217) 
Cd7 (µg/mL) 1 [0.9-2] 4 [3-6] 0.5 [0.3-0.8] 4.00 [1.72-5.39] (<0.001) 0.50 [0.21-0.74] (0.009) 
PK parameters are presented as geometric mean [95% confidence interval] except tmax which is presented as median [interquartile range].  
P-value is calculated usiŶg aŶalǇsis of variaŶce iŶ Stata ϭ5.Ϭ, α=Ϭ.Ϭ5 
 
 
ART = antiretroviral therapy; EFV = Efavirenz-based ART; LPV/r = Ritonavir-boosted lopinavir-based ART 
AUC0-14 days = area under concentration-time curve from 0 hours to 14 days; Cmax = achieved maximum concentration. 
tmax = time to reach maximum concentration, t1/2 = drug elimination half-life; Cd7 = day 7 plasma lumefantrine concentration 
a: p-value oŶlǇ, calculated usiŶg WilcoǆoŶ raŶk suŵ test; α=Ϭ.Ϭ5 
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